Antibacterial agents: Selected publications

Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections
Gomila A, Shaw E, Carratalà J, Leibovici L, Tebé C, Wiegand I, Vallejo-Torres L, Vigo JM, Morris S, Stoddart M, Grier S, Vank C, Cuperus N, Van den Heuvel L, Eliakim-Raz N, Vuong C, MacGowan A, Addy I, Pujol M; COMBACTE-MAGNET WP5- RESCUING Study.
Antimicrob Resist Infect Control. 2018 Sep 14;7:111. doi: 10.1186/s13756-018-0401-6. eCollection 2018.

Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group
Eliakim-Raz N, Babitch T, Shaw E, Addy I, Wiegand I, Vank C, Torre-Vallejo L, Joan-Miquel V, Steve M, Grier S, Stoddart M, Nienke C, van den Heuvel L, Vuong C, MacGowan A, Carratalà J, Leibovici L, Pujol M.
Clin Infect Dis. 2018 May 17. doi: 10.1093/cid/ciy418. [Epub ahead of print]

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study
Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, Grier S, Gibbs J, Vank C, Cuperus N, van den Heuvel L, Eliakim-Raz N, Carratala J, Vuong C, MacGowan A, Babich T, Leibovici L, Addy I, Morris S; RESCUING Study Group and Study Sites.
BMJ Open. 2018 Apr 12;8(4):e020251. doi: 10.1136/bmjopen-2017-020251.

Surveillance for control of antimicrobial resistance
Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J; EPI-Net COMBACTE-MAGNET Group.
Lancet Infect Dis. 2018 Mar;18(3):e99-e106. doi: 10.1016/S1473-3099(17)30485-1. Epub 2017 Nov 5. Review.

The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information
Núñez-Núñez M, Navarro MD, Palomo V, Rajendran NB, Del Toro MD, Voss A, Sharland M, Sifakis F, Tacconelli E, Rodríguez-Baño J; EPI-Net, Combacte-Magnet and EUCIC Group for SUSPIRE.
Clin Microbiol Infect. 2018 Feb;24(2):105-109. doi: 10.1016/j.cmi.2017.07.014. Epub 2017 Jul 24. Review.

Investigational drugs to treat methicillin-resistant Staphylococcus aureus
Vuong C, Yeh AJ, Cheung GY, Otto M.
Expert Opin Investig Drugs. 2016;25(1):73-93. doi: 10.1517/13543784.2016.1109077. Epub 2015 Nov 4.

The Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme – European Public-Private Partnerships for the Development of New Strategies to Tackle Antibiotic Resistance
Kostyanev T, deWinter R, Steel H, Ross S, O’Brien S, François B, Winterhalter M, Stavenger R, Karlén A, Harbarth S, Hackett J, Jafri H, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn S, Bonten M, Goossens H, and for the ND4BB Consortia.
J Antimicrob Chemother. 2016 Feb;71(2):290-5. doi: 10.1093/jac/dkv339. Epub 2015 Nov 15.

How many modes of action should an antibiotic have?
Brötz-Oesterhelt H, Brunner NA.
Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. Review.

Total synthesis and initial structure-activity relationships of longicatenamycin A
von Nussbaum F, Anlauf S, Freiberg C, Benet-Buchholz J, Schamberger J, Henkel T, Schiffer G, Häbich D.
ChemMedChem. 2008 Apr;3(4):619-26.

Structure and total synthesis of lysobactin (katanosin B)
von Nussbaum F, Anlauf S, Benet-Buchholz J, Häbich D, Köbberling J, Musza L, Telser J, Rübsamen-Waigmann H, Brunner NA.
Angew Chem Int Ed Engl. 2007;46(45):8548-52.